Lindsay Burns, PhD

On August 26, the FDA approved Rasonque (daraxonrasib), developed by Revolution Medicines. It is the first broad RAS-targeted inhibitor approved for advanced pancreatic cancer, marking a notable milestone for a disease that has historically had very few options.  For forty years, researchers considered the RAS